In particular, using in vitro and in vivo preclinical cutaneous melanoma (hereafter melanoma) and breast carcinoma models we previously demonstrated Bcl-2 modulation of tumor progression-associated properties and tumor metastatization [10–12]. The gene discussed is BCL2; the disease is melanoma.